Trial Profile
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2023
Price :
$35
*
At a glance
- Drugs Staphylococcus aureus vaccine (Primary) ; Alum
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacodynamics
- 27 Apr 2011 Status changed from recruiting to completed.
- 10 Aug 2010 Nabi Pharmaceuticals is conducting this trial under contract to GlaxoSmithKline.
- 10 Nov 2009 Status changed from planning to recruiting as reported by ClinicalTrials.gov.